Upcoming Investor Conferences for Upstream Bio
Upstream Bio, Inc. (NASDAQ: UPB), based in Waltham, Massachusetts, is gearing up for an exciting December as they participate in significant investor conferences. These events will feature industry insights and serve as a platform for sharing advancements in their innovative research on treatments for inflammatory diseases.
Key Events Scheduled in December
Rand Sutherland, MD, the Chief Executive Officer of Upstream Bio, is scheduled to represent the company in two key investor events this December:
Piper Sandler 37th Annual Healthcare Conference
This event is set for December 2, featuring a fireside chat at 4:30 p.m. ET. Attendees can anticipate in-depth discussions about the company’s strategies and developments in healthcare innovation.
8th Annual Evercore Healthcare Conference
The following event will take place on December 4, at 10:25 a.m. ET. This conference will provide an opportunity for investors to engage with Upstream Bio’s leadership team and explore the company’s future pathways in medicine.
Access to Live Webcasts
Upstream Bio will offer live webcasts of these presentations, which can be accessed through the Events tab on their official website. Interested individuals can also look forward to replays that will be available after the discussions, ensuring that they do not miss any vital information shared during the events.
About Upstream Bio and Their Innovations
Upstream Bio is dedicated to developing novel treatments for inflammatory diseases, focusing first on managing severe respiratory disorders. Their primary product, verekitug, is a groundbreaking monoclonal antibody designed to target the receptor of thymic stromal lymphopoietin (TSLP), a key cytokine involved in inflammatory responses.
This innovative approach positions Upstream Bio at the forefront of tackling chronic diseases, particularly as they advance verekitug into critical Phase 2 trials. These trials prioritize conditions that include chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD).
Commitment to Patient Needs
The team at Upstream Bio is driven by the mission to fulfill unmet needs in patient care. Their ongoing research and dedication aim to offer more effective treatment options for individuals suffering from conditions that are currently inadequately addressed by existing healthcare solutions.
Contact Information for Inquiries
For those who wish to learn more about Upstream Bio or have inquiries, reach out to:
Investor and Media Contact
Meggan Buckwell, Director of Corporate Communications and Investor Relations, can be contacted via email at ir@upstreambio.com.
Frequently Asked Questions
What is Upstream Bio focused on?
Upstream Bio focuses on developing treatments for inflammatory diseases, particularly those affecting severe respiratory conditions.
When and where will the investor conferences take place?
The Piper Sandler Conference is on December 2, and the Evercore Conference is on December 4.
How can I access the presentations?
Live webcasts will be available on the Events section of Upstream Bio’s website on the day of each event, with replays posted afterward.
What is verekitug?
Verekitug is a monoclonal antibody targeting TSLP, currently in Phase 2 trials for various inflammatory conditions.
Who can I contact for more information about Upstream Bio?
You can reach out to Meggan Buckwell for investor and media inquiries via the provided email address.